These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15190528)

  • 1. A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design.
    Zile M; Gaasch W; Little W; Francis G; Tavazzi L; Cleland J; Davies M;
    J Card Fail; 2004 Jun; 10(3):193-9. PubMed ID: 15190528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
    Jang IK; Weissman NJ; Picard MH; Zile MR; Pettigrew V; Shen S; Tatsuno J; Hibberd MG; Tzivoni D; Wackers FJ;
    Am Heart J; 2008 Jan; 155(1):113.e1-8. PubMed ID: 18082500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study.
    Jang IK; Pettigrew V; Picard MH; Kowey PR; Demmel V; Zile MR; Tatsuno J; Wackers FJ; Hibberd M
    J Thromb Thrombolysis; 2005 Dec; 20(3):147-53. PubMed ID: 16261287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
    Voors AA; Shah SJ; Bax JJ; Butler J; Gheorghiade M; Hernandez AF; Kitzman DW; McMurray JJV; Wirtz AB; Lanius V; van der Laan M; Solomon SD
    Eur J Heart Fail; 2018 Nov; 20(11):1601-1610. PubMed ID: 30225882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design.
    Kobayashi S; Wakeyama T; Ono S; Ikeda Y; Omura M; Oda T; Hisamatsu Y; Seki K; Satoh A; Hiromoto M; Akashi S; Uchida K; Harada M; Furutani Y; Nakamura Y; Kohno M; Kawamura S; Obayashi M; Michishige H; Yano M
    J Cardiol; 2020 Apr; 75(4):454-461. PubMed ID: 31866190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure.
    Gao R; Zhang J; Cheng L; Wu X; Dong W; Yang X; Li T; Liu X; Xu Y; Li X; Zhou M
    J Am Coll Cardiol; 2010 May; 55(18):1907-14. PubMed ID: 20430261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
    Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.
    Daubert MA; Yow E; Dunn G; Marchev S; Barnhart H; Douglas PS; O'Connor C; Goldstein S; Udelson JE; Sabbah HN
    Circ Heart Fail; 2017 Dec; 10(12):. PubMed ID: 29217757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial.
    Wang J; Shi J; Wei J; Wang J; Gao K; Li X; Chen J; Li S; Zhao H; Wang W
    Trials; 2017 Oct; 18(1):468. PubMed ID: 29017565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of water extract of stem bark of Terminalia arjuna (Roxb. ex DC.) Wight & Arn. in patients of chronic heart failure: a double-blind, randomized controlled trial.
    Maulik SK; Wilson V; Seth S; Bhargava B; Dua P; Ramakrishnan S; Katiyar CK
    Phytomedicine; 2016 Oct; 23(11):1211-9. PubMed ID: 26988798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
    Chung ES; Miller L; Patel AN; Anderson RD; Mendelsohn FO; Traverse J; Silver KH; Shin J; Ewald G; Farr MJ; Anwaruddin S; Plat F; Fisher SJ; AuWerter AT; Pastore JM; Aras R; Penn MS
    Eur Heart J; 2015 Sep; 36(33):2228-38. PubMed ID: 26056125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
    Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings.
    Patel HC; Hayward C; Dungu JN; Papadopoulou S; Saidmeerasah A; Ray R; Di Mario C; Shanmugam N; Cowie MR; Anderson LJ
    J Card Fail; 2017 Jul; 23(7):517-524. PubMed ID: 28434933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
    Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
    Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
    Hjalmarson A; Goldstein S; Fagerberg B; Wedel H; Waagstein F; Kjekshus J; Wikstrand J; El Allaf D; Vítovec J; Aldershvile J; Halinen M; Dietz R; Neuhaus KL; Jánosi A; Thorgeirsson G; Dunselman PH; Gullestad L; Kuch J; Herlitz J; Rickenbacher P; Ball S; Gottlieb S; Deedwania P
    JAMA; 2000 Mar; 283(10):1295-302. PubMed ID: 10714728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction.
    Zile MR; Bourge RC; Redfield MM; Zhou D; Baicu CF; Little WC
    JACC Heart Fail; 2014 Apr; 2(2):123-30. PubMed ID: 24720918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electropharmacological effects of intracellular Ca
    Sugiyama A; Hagiwara-Nagasawa M; Kambayashi R; Goto A; Chiba K; Ando K; Naito AT; Izumi-Nakaseko H
    J Pharmacol Sci; 2019 Mar; 139(3):180-185. PubMed ID: 30738725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
    Penny WF; Henry TD; Watkins MW; Patel AN; Hammond HK
    Am Heart J; 2018 Jul; 201():111-116. PubMed ID: 29763816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of digitoxin versus trichlormethiazide/amiloride in congestive heart failure NYHA class II/III and sinus rhythm.
    Huonker M; Sorichter S; Schmidt-Trucksäss A; Irmer M; Staiger J; Keul J
    Cardiovasc Drugs Ther; 1999 May; 13(3):233-41. PubMed ID: 10439886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.